Cliff Asness's WST Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 545,879 shares of West Pharmaceutical Services, Inc. (WST) worth $142.95 M, representing 0.09% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in WST, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 440,929 shares. Largest reduction occurred in Q2 2017, reducing 279,239 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's West Pharmaceutical Services (WST) Holding Value Over Time
Track share changes against reported price movement
Quarterly West Pharmaceutical Services (WST) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +24,558 | Add 0.00% | 24,556 | $27.37 |
| Q2 2013 | +14,218 | Add 0.00% | 14,216 | $35.10 |
| Q3 2013 | -14,216 | Sold Out | 14,216 | $0.00 |
| Q4 2014 | +4,112 | New Buy | 4,112 | $53.26 |
| Q1 2015 | -23 | Reduce 0.56% | 4,089 | $60.16 |
| Q2 2015 | -312 | Reduce 7.63% | 3,777 | $57.98 |
| Q3 2015 | +5,928 | Add 156.95% | 9,705 | $54.10 |
| Q4 2015 | +66,619 | Add 686.44% | 76,324 | $60.22 |
| Q1 2016 | +77,333 | Add 101.32% | 153,657 | $69.32 |
| Q2 2016 | +62,890 | Add 40.93% | 216,547 | $75.88 |
| Q3 2016 | +229,329 | Add 105.90% | 445,876 | $74.50 |
| Q4 2016 | +118,963 | Add 26.68% | 564,839 | $84.83 |
| Q1 2017 | +33,320 | Add 5.90% | 598,159 | $81.61 |
| Q2 2017 | -279,239 | Reduce 46.68% | 318,920 | $94.52 |
| Q3 2017 | -37,298 | Reduce 11.70% | 281,622 | $96.26 |
| Q4 2017 | -211,238 | Reduce 75.01% | 70,384 | $98.67 |
| Q1 2018 | -59,261 | Reduce 84.20% | 11,123 | $88.29 |
| Q2 2018 | +2 | Add 0.02% | 11,125 | $99.33 |
| Q3 2018 | +16,251 | Add 146.08% | 27,376 | $123.50 |
| Q4 2018 | +38,621 | Add 141.08% | 65,997 | $98.03 |
| Q1 2019 | +44,258 | Add 67.06% | 110,255 | $110.20 |
| Q2 2019 | +115,145 | Add 104.44% | 225,400 | $125.15 |
| Q3 2019 | +24,462 | Add 10.85% | 249,862 | $141.82 |
| Q4 2019 | -12,169 | Reduce 4.87% | 237,693 | $150.33 |
| Q1 2020 | +6,250 | Add 2.63% | 243,943 | $152.25 |
| Q2 2020 | -129,739 | Reduce 53.18% | 114,204 | $220.39 |
| Q3 2020 | +21,040 | Add 18.42% | 135,244 | $273.25 |
| Q4 2020 | +37,389 | Add 27.65% | 172,633 | $278.27 |
| Q1 2021 | -18,126 | Reduce 10.50% | 154,507 | $278.19 |
| Q2 2021 | -11,302 | Reduce 7.31% | 143,205 | $358.32 |
| Q3 2021 | +869 | Add 0.61% | 144,074 | $424.54 |
| Q4 2021 | -21,541 | Reduce 14.95% | 122,533 | $469.01 |
| Q1 2022 | -17,388 | Reduce 14.19% | 105,145 | $410.71 |
| Q2 2022 | -11,090 | Reduce 10.55% | 94,055 | $297.11 |
| Q3 2022 | -9,559 | Reduce 10.16% | 84,496 | $246.08 |
| Q4 2022 | +15,281 | Add 18.08% | 99,777 | $234.18 |
| Q1 2023 | -50,397 | Reduce 50.51% | 49,380 | $346.47 |
| Q2 2023 | +1,678 | Add 3.40% | 51,058 | $382.47 |
| Q3 2023 | +2,002 | Add 3.92% | 53,060 | $375.21 |
| Q4 2023 | -11,071 | Reduce 20.87% | 41,989 | $352.12 |
| Q1 2024 | -14,569 | Reduce 34.70% | 27,420 | $395.70 |
| Q2 2024 | -9,872 | Reduce 36.00% | 17,548 | $329.39 |
| Q3 2024 | -2,291 | Reduce 13.06% | 15,257 | $300.17 |
| Q4 2024 | -4,279 | Reduce 28.05% | 10,978 | $327.56 |
| Q1 2025 | -6,597 | Reduce 60.09% | 4,381 | $217.45 |
| Q2 2025 | +100,569 | Add 2295.57% | 104,950 | $218.80 |
| Q3 2025 | +440,929 | Add 420.13% | 545,879 | $261.87 |
Cliff Asness's West Pharmaceutical Services Investment FAQs
Cliff Asness first purchased West Pharmaceutical Services, Inc. (WST) in Q4 2012, acquiring 24,556 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held West Pharmaceutical Services, Inc. (WST) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to West Pharmaceutical Services, Inc. (WST) was in Q3 2025, adding 545,879 shares worth $142.95 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 545,879 shares of West Pharmaceutical Services, Inc. (WST), valued at approximately $142.95 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, West Pharmaceutical Services, Inc. (WST) represents approximately 0.09% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in West Pharmaceutical Services, Inc. (WST) was 598,159 shares, as reported at the end of Q1 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.